A phase I study of TAS-102 and irinoteca
Phase 1
- Conditions
- Patients with metastatic colorectal cancer
- Registration Number
- JPRN-jRCT2080222053
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
1) Patients with histologically confirmed metastatic colorectal cancer
2) Patients can be administered orally
3) Patients having a performance status (PS) of Eastern Cooperative Oncology Group (ECOG) 0 or 1
4) Patients without prior irinotecan based chemotherapy
Exclusion Criteria
1) Patient who has serious concomitant disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method